Enanta Pharmaceuticals announces data on eight-week treatment of AbbVie's VIEKIRAX®
Enanta announced new data showing high response rates with just eight weeks of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) treatment. VIEKIRAX + EXVIERA is currently approved in the EU for GT1b patients without cirrhosis for 12 weeks. September 23, 2016